Selangor, Malaysia, May 22, 2026 (GLOBE NEWSWIRE) — Empro Group Inc. (Nasdaq: EMPG) (“Empro Group” or the “Company”), a rising beauty and personal care brand headquartered in Malaysia, today announced that on May 19, 2026 it received a notice from The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company has not yet filed its annual report on Form 20-F for the fiscal year ended December 31, 2025. Under Nasdaq rules, the Company has 60 calendar days to submit a plan to regain compliance and, if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original filing’s due date may be granted, or until November 11, 2026, to regain compliance. If the plan to regain compliance is not accepted, the Company will have the opportunity to appeal...

PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces that the underwriters of its previously announced global offering (the “Global Offering”) have fully exercised their option to purchase 33,805 additional new ordinary shares in the form of additional American Depositary Shares (the “Additional ADSs”) (the “Option”). Each Additional ADS represents one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company and the offering price of $38.98 per Additional ADS corresponds to a price of €33.60 per Ordinary Share (on the basis of an exchange rate...

Houston, TX, May 22, 2026 (GLOBE NEWSWIRE) — ACP Holdings Acquisition Corp. (Nasdaq: ACGCU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 21,461,600 units, which includes 1,461,600 units issued pursuant to the partial exercise by the underwriter of its overallotment option, completed on April 8, 2026 (the “Offering”), may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about May 28, 2026. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol “ACGCU”, and each of the Class A ordinary shares and warrants will separately trade on The Nasdaq Global Market under the symbols “ACGC” and “ACGCW,” respectively. No fractional warrants will be issued upon separation of the units and only whole...

SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026. SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309. The reverse stock split was approved by SCYNEXIS’s stockholders at SCYNEXIS’s Special Meeting held on May 19, 2026, with the final ratio subsequently determined...

Company expects to file 2025 Form 10-K on or prior to June 15 First quarter 2026 Form 10-Q expected to follow promptly after annual filing NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (NASDAQ: NKLR) (“Terra” or the “Company”), a Nasdaq listed company, today disclosed receipt of a Nasdaq Listing Delinquency Letter and provided an update on the timing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Terra Innovatum continues to work diligently to complete its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. As previously disclosed, the Company is taking the necessary time to ensure the filing is aligned with its post-combination reporting requirements and accurately reflects the...

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — In connection with Japan Smaller Capitalization Fund, Inc. (the “Fund”) (NYSE: JOF)’s previously announced conditional tender offer, the Fund today announced that its Board of Directors (the “Board”) has approved a tender offer (the “Tender Offer”) to purchase up to 10% of its issued and outstanding shares at a price per share equal to 98% of the net asset value (“NAV”) per share as of the pricing date. The Tender Offer is expected to commence on June 1, 2026, and expire at 5:00 p.m. on July 1, 2026 (the “Expiration Date”), with a pricing date of July 2, 2026, unless extended. If more shares are tendered than the maximum amount specified in the offer, the Fund intends to purchase shares from tendering shareholders on a pro rata basis, based on the number of shares tendered by each shareholder. The...

Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and older First European launch expected in Germany in Q3 2026 Approval adds to Joenja® approvals in the United States, United Kingdom, Japan, Australia and Israel, supporting Pharming’s global expansion strategyLeiden, the Netherlands, May 22, 2026: Pharming Group (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that the European Commission (EC) has granted marketing authorization for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in adult and...

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQX: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) set August 18, 2026, for its annual general and special meeting (“AGM”), when it will also fulfil the requisition of Waratah Capital Advisors Ltd. (“Waratah”) for a shareholder meeting to address board renewal. On recommendation of Lithium Ionic’s special committee, the board of the Company has called the shareholder meeting to address typical annual matters, including the election of members of the board of directors for the ensuing year. The Company anticipates continued discussion with representatives of Waratah and other shareholders to identify further directors for nomination. Shareholders will be aware that certain directors have ceased to be members of the Company’s board of directors and have...